OSCE stationDrNB Cardiology – Viva master list

Cardiac MRI viva list

22 cases · 110 viva questionsLast reviewed: October 2026
Merit MedScript seal

The CMR images examiners show most often: infarction, viability and stress perfusion, cardiomyopathies and myocarditis, and masses, flow and congenital disease. Each entry gives the imaging sign to point at, the diagnosis, the clinical risk and the next step, followed by five examiner cross-examination questions.

How to present in the viva: Name the sequence first (cine, T2/oedema, first-pass perfusion, LGE, T1/T2 mapping, T2*). Then describe the LGE pattern — subendocardial or transmural in a coronary territory versus mid-wall, subepicardial or diffuse — and finish with the diagnosis and next step.

AIschaemic heart disease and viability

1.Myocardial infarction (CMR)

  • Imaging hallmark: Subendocardial or transmural LGE in a coronary territory.
  • Diagnosis: Prior myocardial infarction
  • Clinical risk: Heart failure, VT, LV thrombus.
  • Management: Secondary prevention and HF GDMT; ICD by LVEF criteria.
Viva questions (5)
  • Q: What confirms ischaemic aetiology?A: LGE involving the subendocardium in a coronary distribution.
  • Q: Microvascular obstruction?A: Dark, non-enhancing core within bright LGE early after MI.
  • Q: Prognosis of MVO?A: Adverse — larger infarcts, worse remodelling and outcomes.
  • Q: How is viability assessed?A: Transmural extent of LGE.
  • Q: Rule of thumb?A: LGE <50% of wall thickness — function likely to recover after revascularisation.

2.Myocardial viability

  • Imaging hallmark: CMR: LGE <50% transmurality with dysfunctional segments. PET: perfusion–metabolism mismatch (reduced flow, preserved FDG).
  • Diagnosis: Hibernating myocardium
  • Clinical risk: Progressive ischaemic cardiomyopathy.
  • Management: Heart Team revascularisation decision — viability predicts functional recovery but not survival benefit (STICH, REVIVED-BCIS2).
Viva questions (5)
  • Q: PET mismatch?A: Reduced flow (ammonia or rubidium) with preserved FDG uptake — viable.
  • Q: PET match?A: Concordantly reduced flow and FDG — scar.
  • Q: CMR transmurality bands?A: 1–25% likely viable, 26–50% intermediate, >50% unlikely to recover.
  • Q: 5-point LGE scale?A: 0, 1–25, 26–50, 51–75, 76–100% transmural.
  • Q: Wall thickness?A: End-diastolic thickness <5.5 mm suggests non-viable scar.

3.Microvascular obstruction (CMR)

  • Imaging hallmark: Dark hypo-enhanced core inside bright subendocardial or transmural LGE early after reperfused STEMI.
  • Diagnosis: Acute MI with microvascular obstruction
  • Clinical risk: Adverse remodelling, LV thrombus, worse prognosis.
  • Management: Full post-MI therapy; MVO marks no-reflow despite an open epicardial artery.
Viva questions (5)
  • Q: Why is the core dark?A: Destroyed capillaries prevent contrast entering.
  • Q: Does MVO persist?A: No — replaced by scar over weeks to months.
  • Q: Best sequence?A: Early gadolinium enhancement (1–3 min) and LGE (10–15 min).
  • Q: Effect on LV function?A: Less recovery and more remodelling.
  • Q: Cath-lab equivalent?A: No-reflow: TIMI flow ≤2 or myocardial blush grade 0–1 after PCI.

4.Intramyocardial haemorrhage (CMR)

  • Imaging hallmark: Dark core on T2* (and T2) imaging within the infarct, from haemoglobin breakdown products.
  • Diagnosis: Haemorrhagic myocardial infarction
  • Clinical risk: Adverse remodelling and worse outcomes; associated with rupture and aneurysm.
  • Management: Full post-MI therapy and close follow-up.
Viva questions (5)
  • Q: How does it differ from MVO?A: MVO is lack of perfusion (dark on LGE); IMH is bleeding (dark on T2*).
  • Q: Do they coexist?A: Yes — IMH almost always lies within MVO.
  • Q: Cause?A: Severe reperfusion injury with capillary rupture.
  • Q: Timing?A: Develops within the first days after reperfusion.
  • Q: Long-term consequence?A: Residual iron in the scar, which may promote inflammation and arrhythmia.

5.Vasodilator stress perfusion CMR

  • Imaging hallmark: Subendocardial perfusion defect at peak vasodilator stress that is absent at rest, without matching LGE, following a coronary territory.
  • Diagnosis: Inducible myocardial ischaemia
  • Clinical risk: Haemodynamically significant CAD.
  • Management: Optimal medical therapy; invasive angiography for extensive ischaemia (e.g. ≥2 of 16 segments) or refractory symptoms.
Viva questions (5)
  • Q: How does adenosine work?A: A2A agonist causing maximal microvascular dilatation; territories beyond a stenosis cannot increase flow.
  • Q: Why subendocardial?A: The subendocardium is most vulnerable; defects confined to the epicardium are not ischaemic.
  • Q: Dark-rim artefact?A: Transient subendocardial rim from Gibbs ringing or motion — appears early and fades, unlike true defects.
  • Q: Adenosine reversal?A: Stop the infusion (half-life seconds); aminophylline if effects persist.
  • Q: Contraindications?A: Active bronchospasm, second- or third-degree AV block without a pacemaker, hypotension, recent caffeine.

BCardiomyopathies and myocarditis

6.Cardiac sarcoidosis (CMR)

  • Imaging hallmark: Patchy multifocal mid-wall or subepicardial LGE in a non-coronary distribution, typically basal septum (often both sides — ‘hook sign’) and inferolateral wall.
  • Diagnosis: Cardiac sarcoidosis
  • Clinical risk: VT, complete heart block, heart failure, sudden death.
  • Management: Immunosuppression for active inflammation (FDG-PET guided); ICD by risk criteria (VT, LVEF ≤35%, pacing indication, significant LGE).
Viva questions (5)
  • Q: Commonest sites?A: Basal septum and basal inferolateral wall.
  • Q: T2 mapping?A: Raised in active granulomatous inflammation (oedema).
  • Q: How does it differ from ischaemic LGE?A: Ischaemic LGE always involves the subendocardium in a coronary territory.
  • Q: Why add FDG-PET?A: CMR shows scar; PET shows active inflammation to guide steroids.
  • Q: PET preparation?A: High-fat, very-low-carbohydrate diet and prolonged fast (± heparin) to suppress normal myocardial glucose uptake.

7.Hypertrophic cardiomyopathy (CMR)

  • Imaging hallmark: Asymmetric (usually septal) hypertrophy ≥15 mm with patchy mid-wall LGE in the hypertrophied segments and at RV insertion points.
  • Diagnosis: Hypertrophic cardiomyopathy
  • Clinical risk: Sudden death, LVOT obstruction, AF, heart failure.
  • Management: Beta-blocker or myosin inhibitor; septal reduction for refractory obstruction; ICD by risk stratification.
Viva questions (5)
  • Q: Why LGE at the insertion points?A: Mechanical stress and myocyte disarray at the hinge points.
  • Q: Does extent of LGE matter?A: Yes — LGE ≥15% of LV mass is a risk marker for sudden death (ACC/AHA 2024: ICD reasonable).
  • Q: What is SAM?A: Systolic anterior motion of the mitral valve, seen on cine CMR.
  • Q: Apical HCM?A: Hypertrophy confined to the apex — ‘ace-of-spades’ cavity in diastole; watch for apical aneurysm.
  • Q: How does athlete's heart differ?A: Wall usually ≤13–15 mm, dilated cavity, normal diastolic function, no LGE, regresses with detraining.

8.Cardiac amyloidosis (CMR)

  • Imaging hallmark: Diffuse global subendocardial or transmural LGE with abnormal nulling; markedly raised native T1 and ECV (>40%).
  • Diagnosis: Cardiac amyloidosis
  • Clinical risk: Restrictive heart failure, conduction disease, arrhythmia.
  • Management: Screen for a monoclonal protein (sFLC, SIFE, UIFE) and do bone scintigraphy; tafamidis/acoramidis/vutrisiran for ATTR, chemotherapy for AL.
Viva questions (5)
  • Q: What is abnormal nulling?A: The myocardium nulls at the same time as or before the blood pool (normally the blood nulls first).
  • Q: Native T1?A: Markedly elevated.
  • Q: ECV?A: Greatly expanded, often >40%.
  • Q: AL or ATTR — which is commoner?A: Wild-type ATTR, increasingly recognised in elderly HFpEF and aortic stenosis.
  • Q: Gadolinium in severe renal failure?A: Use group II macrocyclic agents if eGFR <30 (NSF risk is very low); native T1 needs no contrast.

9.ARVC (CMR)

  • Imaging hallmark: Regional RV akinesia, dyskinesia or dyssynchrony with RV dilatation or dysfunction; RV aneurysms; LGE (often also LV subepicardial).
  • Diagnosis: Arrhythmogenic right ventricular cardiomyopathy
  • Clinical risk: VT (LBBB morphology) and sudden death.
  • Management: ICD by risk; stop competitive and endurance exercise; beta-blockers.
Viva questions (5)
  • Q: Triangle of dysplasia?A: RV inflow, outflow and apex (newer data favour subtricuspid and outflow regions).
  • Q: Why CMR?A: Best for RV volumes, regional motion and tissue characterisation.
  • Q: Is fat alone diagnostic?A: No — Task Force criteria need wall-motion abnormality plus RV dilatation or dysfunction.
  • Q: ECG correlate?A: Epsilon waves and T inversion in V1–V3.
  • Q: Genetics?A: Desmosomal genes, especially PKP2.

10.Acute myocarditis (CMR)

  • Imaging hallmark: Subepicardial or mid-wall LGE (classically basal inferolateral) with raised T2 or T2 signal (oedema) and raised native T1/ECV — 2018 Lake Louise criteria.
  • Diagnosis: Acute myocarditis
  • Clinical risk: Ventricular arrhythmias, heart failure, cardiogenic shock.
  • Management: Supportive care and HF GDMT; avoid competitive sport for 3–6 months; biopsy if fulminant or not improving.
Viva questions (5)
  • Q: 2018 Lake Louise criteria?A: At least one T2-based criterion (oedema) plus at least one T1-based criterion (raised native T1, ECV or non-ischaemic LGE).
  • Q: Classic LGE site?A: Basal inferolateral wall, subepicardial or mid-wall.
  • Q: How does it differ from MI?A: MI LGE always involves the subendocardium in a coronary territory.
  • Q: Role of parametric mapping?A: T1 and T2 mapping detect diffuse oedema and injury that weighted images miss.
  • Q: Common causes?A: Viruses (parvovirus B19, HHV-6, enteroviruses, SARS-CoV-2), drugs including checkpoint inhibitors, autoimmune disease.

11.Myocardial iron overload

  • Imaging hallmark: Reduced myocardial T2* on gradient-echo imaging (mid-septum): <20 ms abnormal, <10 ms severe.
  • Diagnosis: Cardiac siderosis (transfusional or haemochromatosis)
  • Clinical risk: Heart failure (often reversible), arrhythmias including AF.
  • Management: Intensified iron chelation (deferiprone has the best cardiac effect; combine with deferoxamine if severe); serial T2*.
Viva questions (5)
  • Q: Severe overload?A: T2* below 10 ms — high risk of heart failure.
  • Q: Normal T2*?A: Above 20 ms.
  • Q: Liver or heart first?A: Liver loads first; cardiac loading follows and the two correlate poorly, so the heart must be measured directly.
  • Q: Appearance?A: Myocardium darkens rapidly on gradient-echo images (signal loss).
  • Q: Commonest cause in India?A: Transfusion-dependent thalassaemia major.

12.Anderson–Fabry disease (CMR)

  • Imaging hallmark: Concentric LVH with low native T1 (sphingolipid) and basal inferolateral mid-wall LGE (where T1 may pseudonormalise).
  • Diagnosis: Anderson–Fabry disease
  • Clinical risk: HFpEF, arrhythmias and conduction disease, stroke, renal failure.
  • Management: Enzyme replacement (agalsidase alfa or beta, pegunigalsidase) or migalastat for amenable variants; family screening.
Viva questions (5)
  • Q: Pathophysiology?A: Alpha-galactosidase A deficiency with globotriaosylceramide accumulation.
  • Q: Why is native T1 low?A: Intracellular lipid shortens T1 — unlike amyloid or fibrosis, which raise it.
  • Q: Classic LGE?A: Basal inferolateral mid-wall.
  • Q: ECG?A: Short PR early, LVH, later AV block and bradycardia.
  • Q: Inheritance?A: X-linked — men are severely affected, but heterozygous women are often affected too.

13.Apical hypertrophic cardiomyopathy (CMR)

  • Imaging hallmark: Apical wall thickening with an ‘ace-of-spades’ LV cavity in diastole on 4-chamber cine; apical LGE; possible apical aneurysm.
  • Diagnosis: Apical HCM (Yamaguchi)
  • Clinical risk: Apical aneurysm with thrombus, VT, AF.
  • Management: Beta-blocker; anticoagulation if thrombus; ICD reasonable with apical aneurysm (ACC/AHA 2024).
Viva questions (5)
  • Q: Classic ECG?A: Giant negative T waves (>10 mm) in precordial leads.
  • Q: LVOT obstruction?A: Usually not; mid-cavity obstruction may occur.
  • Q: Why CMR over echo?A: Echo can miss the apex because of near-field artefact and foreshortening.
  • Q: Apical pouch?A: Thin-walled apical aneurysm distal to mid-cavity obstruction.
  • Q: Population?A: Commoner in East Asians (Japan).

14.Non-ischaemic dilated cardiomyopathy (CMR)

  • Imaging hallmark: Dilated, globally hypokinetic LV; mid-wall linear septal LGE (‘stria’) in about a third.
  • Diagnosis: Non-ischaemic DCM
  • Clinical risk: Progressive HF, VT, sudden death.
  • Management: GDMT; CRT-D if LVEF ≤35% with LBBB and QRS ≥150 ms; LGE and genotype refine ICD decisions.
Viva questions (5)
  • Q: What does mid-wall LGE mean?A: Replacement fibrosis — independent predictor of VT and sudden death.
  • Q: How common?A: About 30–35%.
  • Q: How to exclude ischaemic cause?A: No subendocardial LGE and unobstructed coronaries.
  • Q: T1 mapping?A: Native T1 and ECV raised by diffuse interstitial fibrosis.
  • Q: Reversible causes?A: Tachycardia-induced, alcohol, peripartum, some myocarditis.

15.Endomyocardial fibrosis and Löffler endocarditis

  • Imaging hallmark: Apical obliteration with subendocardial LGE and overlying thrombus — the ‘double-V’ sign (myocardium, enhancing endocardium, dark thrombus).
  • Diagnosis: Endomyocardial disease (hypereosinophilic / tropical EMF)
  • Clinical risk: Restrictive physiology, thromboembolism, AV valve regurgitation.
  • Management: Löffler: corticosteroids (imatinib if FIP1L1-PDGFRA), anticoagulation, HF therapy. Advanced EMF: endocardiectomy and valve repair.
Viva questions (5)
  • Q: Key lab finding in Löffler?A: Peripheral eosinophilia (hypereosinophilic syndrome).
  • Q: What is the double-V sign?A: Three layers at the obliterated apex: normal myocardium, enhancing fibrotic endocardium and a dark thrombus layer.
  • Q: How does it differ from apical HCM?A: HCM is thick muscle; EMF is thick fibrous endocardium with thrombus and a small cavity.
  • Q: Ventricles involved?A: Often both.
  • Q: Indian relevance?A: Tropical EMF is endemic in Kerala and other coastal regions.

16.Chagas cardiomyopathy (CMR)

  • Imaging hallmark: Narrow-necked LV apical aneurysm and basal inferolateral mid-wall or transmural LGE with normal coronaries.
  • Diagnosis: Chronic Chagas cardiomyopathy
  • Clinical risk: Apical thrombus and stroke, VT, sudden death, progressive HF.
  • Management: HF therapy, amiodarone and ICD for VT, anticoagulation for thrombus; benznidazole in early or indeterminate disease.
Viva questions (5)
  • Q: Endemic region?A: Latin America (Trypanosoma cruzi).
  • Q: Typical LGE?A: Basal inferolateral and apical, mid-wall or transmural.
  • Q: Aneurysm shape?A: Narrow-necked, ‘finger-like’ apical aneurysm — unlike the wide-necked post-MI aneurysm.
  • Q: Classic ECG?A: RBBB with LAFB.
  • Q: Pathogenesis?A: Parasite persistence with immune-mediated myocarditis and dysautonomia.

17.Arrhythmogenic left ventricular cardiomyopathy (CMR)

  • Imaging hallmark: Ring-like subepicardial or mid-wall LV LGE, often with normal or mildly reduced LVEF.
  • Diagnosis: Left-dominant arrhythmogenic cardiomyopathy
  • Clinical risk: VT and sudden death out of proportion to LV dysfunction.
  • Management: ICD by risk (Class I after VT/VF; consider with DSP/FLNC variants and LVEF <45–50%, NSVT or extensive LGE); avoid intense exercise.
Viva questions (5)
  • Q: Common genes?A: Desmoplakin (DSP) and filamin C (FLNC).
  • Q: How does it differ from ARVC?A: Predominant LV involvement; RV may be normal.
  • Q: Why CMR?A: Echo may be normal early; only LGE shows the subepicardial scar.
  • Q: VT morphology?A: RBBB (LV origin).
  • Q: Myocarditis-like episodes?A: Yes — DSP cardiomyopathy can present with chest pain and troponin rise (‘hot phases’).

18.Takotsubo syndrome (CMR)

  • Imaging hallmark: Apical ballooning with oedema (raised T2) in the dysfunctional segments and no significant LGE.
  • Diagnosis: Takotsubo (stress) cardiomyopathy
  • Clinical risk: Acute HF, shock, LVOT obstruction, LV thrombus, arrhythmia.
  • Management: Supportive care; avoid inotropes if LVOT obstruction; anticoagulate if thrombus; function usually recovers within weeks.
Viva questions (5)
  • Q: Key discriminator from anterior MI?A: No significant LGE, oedema beyond a single coronary territory, unobstructed coronaries.
  • Q: Why high T2?A: Transient myocardial oedema.
  • Q: Which segments are hyperkinetic?A: Basal segments in the typical apical form.
  • Q: Variants?A: Mid-ventricular, basal (inverted) and focal.
  • Q: Triggers?A: Emotional or physical stress with catecholamine surge; commonest in postmenopausal women.

CMasses, flow and congenital heart disease

19.Cardiac masses (CMR)

  • Imaging hallmark: First-pass perfusion and LGE separate vascular tumours from avascular thrombus; T1/T2 and fat suppression type the tumour.
  • Diagnosis: Cardiac mass — tissue characterisation
  • Clinical risk: Embolism, obstruction, arrhythmia.
  • Management: Resection for tumours; anticoagulation for thrombus.
Viva questions (5)
  • Q: Thrombus on CMR?A: No perfusion and no enhancement — dark on long-TI LGE.
  • Q: Myxoma?A: Heterogeneous mass with patchy enhancement, stalk to the interatrial septum (fossa ovalis), usually LA.
  • Q: Lipoma?A: Bright on T1-weighted images and suppresses with fat saturation.
  • Q: Fibroma?A: Very intense homogeneous LGE; typically in the ventricular septum of children.
  • Q: Commonest primary malignant tumour?A: Angiosarcoma — usually right atrium, heterogeneous and avidly enhancing.

20.Phase-contrast flow (Qp:Qs)

  • Imaging hallmark: Phase-contrast flow in the main PA and ascending aorta gives Qp:Qs; ≥1.5 indicates a significant shunt.
  • Diagnosis: Left-to-right shunt quantification
  • Clinical risk: RV or LV volume overload and pulmonary hypertension.
  • Management: Closure decisions combine Qp:Qs, ventricular volumes and PVR.
Viva questions (5)
  • Q: Where is flow measured?A: Main pulmonary artery and ascending aorta, perpendicular to flow.
  • Q: Qp:Qs 1.0?A: No net shunt.
  • Q: Qp:Qs <1.0?A: Net right-to-left shunt (e.g. Eisenmenger, unrepaired cyanotic disease).
  • Q: Can it quantify regurgitation?A: Yes — forward and reverse flow give the regurgitant volume and fraction.
  • Q: Source of error?A: Background phase offset from eddy currents, plus aliasing if the VENC is set too low.

21.Ebstein anomaly (CMR)

  • Imaging hallmark: Apical displacement of the septal tricuspid leaflet ≥8 mm/m² with an atrialised RV; CMR measures functional RV volume and EF.
  • Diagnosis: Ebstein anomaly
  • Clinical risk: RV failure, severe TR, accessory pathways (WPW), paradoxical embolism.
  • Management: Cone reconstruction for symptoms, exercise decline, progressive RV dilatation or dysfunction.
Viva questions (5)
  • Q: Why CMR over echo?A: Accurate RV volumes and EF in a distorted RV.
  • Q: Atrialised RV?A: Myocardium between the true annulus and the displaced leaflet attachments.
  • Q: Functional RV?A: The trabecular and outflow portions beyond the displaced leaflets.
  • Q: LGE?A: Uncommon; may appear in advanced disease.
  • Q: Associated defect?A: Interatrial communication (ASD or PFO) in most patients.

22.Cardiac lipoma (CMR/CT)

  • Imaging hallmark: Encapsulated mass, homogeneously bright on T1-weighted images, suppressing completely on fat-saturated sequences; no enhancement.
  • Diagnosis: Cardiac lipoma
  • Clinical risk: Arrhythmia or obstruction if large.
  • Management: Observation; surgery only if symptomatic.
Viva questions (5)
  • Q: Common sites?A: Right atrium, LV and epicardial surface.
  • Q: Lipomatous hypertrophy of the septum?A: Unencapsulated fat in the interatrial septum, sparing the fossa ovalis (‘dumbbell’).
  • Q: Enhancement?A: None — avascular.
  • Q: CT density?A: Fat attenuation, about −50 to −100 HU.
  • Q: Malignant counterpart?A: Liposarcoma — heterogeneous, invasive and enhancing.

Classes and cut-offs follow the ESC 2020–2024 and ACC/AHA guidelines current in October 2026; always apply your own institution's protocols.

meritmedscript.comDr. Sidhartha Mullapudi